[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN115400189A - Glycolipid-synergestic traditional Chinese medicine composition, extract, preparation method, application and preparation - Google Patents

Glycolipid-synergestic traditional Chinese medicine composition, extract, preparation method, application and preparation Download PDF

Info

Publication number
CN115400189A
CN115400189A CN202210952235.5A CN202210952235A CN115400189A CN 115400189 A CN115400189 A CN 115400189A CN 202210952235 A CN202210952235 A CN 202210952235A CN 115400189 A CN115400189 A CN 115400189A
Authority
CN
China
Prior art keywords
chinese medicine
traditional chinese
parts
medicine composition
noni
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210952235.5A
Other languages
Chinese (zh)
Other versions
CN115400189B (en
Inventor
郭姣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Changgeng Pharmaceutical Technology Co ltd
Original Assignee
Guangdong Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Pharmaceutical University filed Critical Guangdong Pharmaceutical University
Priority to CN202210952235.5A priority Critical patent/CN115400189B/en
Publication of CN115400189A publication Critical patent/CN115400189A/en
Application granted granted Critical
Publication of CN115400189B publication Critical patent/CN115400189B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/746—Morinda
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a glycolipid-synergestic traditional Chinese medicine composition, an extract, a preparation method, application and a preparation. The traditional Chinese medicine composition comprises the following raw materials: fingered citron, chinese yam, hawthorn, momordica grosvenori, polygonatum and noni; the preparation method comprises the following steps: s1, drying and crushing fingered citron, chinese yam, hawthorn, momordica grosvenori and sealwort according to the formula amount to obtain fine powder; s2, mixing the fine powder obtained in the step S1 with noni fruits according to the formula amount to obtain the traditional Chinese medicine composition. The extract is prepared by extracting the traditional Chinese medicine composition. Under the guidance of the theory of the method of regulating liver, promoting pivot and eliminating turbid pathogen, the invention selects fingered citron, chinese yam, hawthorn, momordica grosvenori, polygonatum and noni as main raw materials, and exerts better technical effect of glycolipid homoordination through the synergistic effect of the fingered citron, the momordica grosvenori and noni. In addition, the raw materials of the invention are all taken from food raw materials, so the invention has high safety, can be used for a long time and has no damage to other visceral organs.

Description

Glycolipid-synergestic traditional Chinese medicine composition, extract, preparation method, application and preparation
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a glycolipid-synergestic traditional Chinese medicine composition, an extract, a preparation method, application and a preparation.
Background
Diabetes Mellitus (DM) is a metabolic disease characterized by a relative or absolute deficiency of insulin, which causes hyperglycemia and, in turn, a metabolic disorder of three major nutrients, insulin absolute deficiency is type 1 Diabetes and insulin relative deficiency is type 2 Diabetes.
Atherosclerosis is a major complication of diabetes and is an important cause of death and disability of diabetic patients, and clinical observation shows that the type 1 or type 2 diabetes is often accompanied by atherosclerotic cardiovascular and cerebrovascular diseases. The death of diabetes patients caused by myocardial infarction accounts for 75-80% of the death of diabetes patients. Similarly, in the coronary heart disease population, the hyperglycemia population accounts for 2/3 of the total population, atherosclerosis is often accompanied by the rise of blood lipids, especially cholesterol, which is a risk factor for cardiovascular diseases such as coronary heart disease, myocardial infarction, and the like.
On the other hand, the existing hypoglycemic drugs include insulin, biguanides, sulfonylureas, alpha-glucosidase inhibitors, insulin sensitizers and the like. However, the above drugs have limitations, such as biguanide hypoglycemic drugs have great damage to intestines and stomach, which easily causes dyspepsia; sulfonylureas may cause leukopenia; the alpha-glycosidase inhibitor can generate gastrointestinal tract reaction, and specifically shows abdominal distension, gastrectasia, epigastric pain, diarrhea or constipation and the like; insulin sensitisers may then cause water retention to occur. However, the most common hypolipidemic drugs in the prior art are HMG-CoA reductase inhibitors, specifically lovastatin, simvastatin, pravastatin, mevastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin and the like, however, statins easily cause liver enzyme increase and may cause liver function change, and some patients have symptoms of muscle pain after taking the medicine, and individually even cause muscle lysis.
CN110354221A discloses a blood sugar reducing composition which comprises 6-12 parts of medlar, 6-10 parts of gordon euryale seed, 10-15 parts of polygonatum odoratum, 8-15 parts of hawthorn, 10-15 parts of fingered citron, 5-10 parts of chrysanthemum, 4-8 parts of liquorice, 8-13 parts of lotus leaf, 10-14 parts of pawpaw, 20-25 parts of coix seed and 25-35 parts of quail egg.
CN111686200A discloses a traditional Chinese medicine composition for treating diabetes, which comprises the following raw materials in parts by mass: 20 to 30 parts of astragalus, 20 to 30 parts of codonopsis pilosula, 40 to 60 parts of rhizoma polygonati, 20 to 30 parts of medlar, 20 to 30 parts of glossy privet fruit, 30 to 50 parts of polygonatum and 20 to 30 parts of angelica. The traditional Chinese medicine composition provided by the invention has the effects of reducing blood sugar and improving diabetic complications.
At present, the traditional Chinese medicine composition for regulating glycolipid metabolism is less researched, but the traditional Chinese medicine composition for reducing blood fat has single function and poor blood fat reducing effect and cannot meet the clinical requirement. Glycolipid Metabolic disease (GLMD) is a complex disease characterized by sugar and lipid metabolism disorder and involving multiple factors such as heredity, environment, spirit and the like. The core mechanism mainly comprises: neuroendocrine disorders, insulin resistance, oxidative stress, inflammation, and gut flora disorders. The clinical characteristics mainly include single or combined symptoms such as hyperglycemia, blood fat imbalance, non-alcoholic fatty liver, overweight, hypertension, atherosclerosis and the like. The applicant team provides a comprehensive integrated treatment strategy of regulating liver and promoting pivot and eliminating turbid aiming at the concept of glycolipid metabolic disease. The strategy emphasizes that the liver is taken as the core and hub of the glycolipid metabolism disease, and the prevention and treatment break through the limitation of single-disease single-treatment of the current glucose and lipid metabolism disorder diseases.
Disclosure of Invention
The invention aims to provide a glycolipid-syngulated traditional Chinese medicine composition, an extract, a preparation method, application and a preparation under the guidance of the theory of the liver-regulating pivot-promoting turbid-removing method.
In order to achieve the purpose, the invention adopts the following technical scheme:
a Chinese medicinal composition with sugar and lipid concoction comprises fructus Citri Sarcodactylis, rhizoma Dioscoreae, fructus crataegi, fructus Siraitiae Grosvenorii and rhizoma Polygonati.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 8-15 parts of fingered citron, 15-32 parts of Chinese yam, 9-12 parts of hawthorn, 9-15 parts of momordica grosvenori and 16-25 parts of rhizoma polygonati.
Preferably, the traditional Chinese medicine composition also comprises 6-12 parts by weight of noni fruits.
Preferably, the noni is noni pulp and the soluble solids are 7.0-9.0%.
Fingered citron: sweet, pungent and bitter with warm nature, enters liver, stomach and spleen meridians. Has effects of dispersing stagnated liver qi, regulating qi-flowing, regulating stomach function and relieving pain. Modern researches show that the main chemical components of the fingered citron comprise various physiological active substances such as volatile oil, flavonoid, coumarins, polysaccharide, amino acid, inorganic salt and the like, and the fingered citron has the effects of regulating immunity, resisting oxidation, reducing blood sugar, regulating lipid, resisting insulin resistance, resisting inflammation, relieving pain and the like.
Chinese yam: sweet in flavor and neutral in nature, entering lung, spleen and kidney meridians. Has effects in invigorating spleen, tonifying lung, reinforcing stomach, invigorating kidney, reinforcing kidney, replenishing vital essence, improving hearing and eyesight, nourishing five internal organs, and strengthening muscle and bone. Research shows that the Chinese yam has the pharmacological effects of improving immunity, improving digestion, reducing blood sugar, reducing blood fat, resisting oxidation, delaying senescence, resisting tumors and mutation, promoting kidney regeneration and repair, regulating acid-base balance and the like.
Hawthorn fruit: sour and sweet in taste, slightly warm in nature, entering spleen, stomach and liver meridians. Has effects of resolving food stagnation, invigorating stomach, activating qi-flowing, dispelling blood stasis, eliminating turbid pathogen, and reducing blood lipid. Researches show that the main components of the hawthorn comprise terpenes, flavonoids, organic acids, aromatic compounds and the like, and the hawthorn has the pharmacological effects of preventing cardiovascular diseases, improving heart vitality, exciting the central nervous system, reducing blood pressure, reducing cholesterol, softening blood vessels, resisting tumors, protecting liver and the like.
Momordica grosvenori: sweet in flavor and cool in nature, and enters lung and large intestine meridians. Has effects of clearing heat, moistening lung, relieving cough, relieving sore throat, and relieving constipation. Modern researches show that the momordica grosvenori contains mogroside, fructose, amino acid, flavone, D-mannitol, glucose and other components, and has the pharmacological effects of reducing blood pressure, reducing blood sugar, resisting tumors, delaying senescence and the like.
Rhizoma polygonati: sweet in flavor and neutral in nature, and entering spleen, lung and kidney meridians. Has effects in invigorating qi, nourishing yin, invigorating spleen, moistening lung, and invigorating kidney. Modern researches show that rhizoma polygonati contains rhizoma polygonati polysaccharide, oligosaccharide, mucilaginous substances, starch, various amino acids and other components, and has pharmacological effects of improving body immunity, promoting lymphocyte transformation, resisting mycobacterium tuberculosis, reducing blood fat, reducing blood sugar and the like.
Noni (Noni) is the fruit of morinda citrifolia. Noni is shrub to small arbor, 1-5 m high, straight stem, with branches close to quadrangular shape. The leaves are alternately opposite, oblong, oval or oval, 12-25 cm long, tapered or sharp at both ends, generally glossy, hairless, full-rimmed. Modern researches show that the noni ferment has the effects of reducing blood pressure, regulating blood fat, improving osteoporosis and hearing ability, resisting fatigue, enhancing memory, repairing wounds and the like.
The technical effects of the invention can be realized by the above technical schemes, but in some preferred embodiments, the achieved technical effects are superior to other schemes.
For example:
the proportion of fingered citron, momordica grosvenori and noni is 5:5:4, wherein the preferable traditional Chinese medicine composition comprises the following specific components in parts by weight: 12 parts of fingered citron, 18 parts of Chinese yam, 11 parts of hawthorn, 12 parts of momordica grosvenori, 24 parts of rhizoma polygonati and 10 parts of noni.
Most preferably, the traditional Chinese medicine composition comprises the following specific components in parts by weight: 10 parts of fingered citron, 20 parts of Chinese yam, 10 parts of hawthorn, 10 parts of momordica grosvenori, 20 parts of rhizoma polygonati and 8 parts of noni.
The invention also provides a preparation method of the glycolipid-synergestic traditional Chinese medicine composition, which comprises the following steps:
s1, drying and crushing fingered citron, chinese yam, hawthorn, momordica grosvenori and sealwort according to the formula ratio to obtain fine powder;
and S2, mixing the fine powder obtained in the step S1 with noni fruit in a formula amount to obtain the traditional Chinese medicine composition.
The invention also provides a traditional Chinese medicine extract with the same glycolipid, which is extracted from the traditional Chinese medicine composition.
Preferably, the extraction includes, but is not limited to: decocting with water, soaking, percolating, modifying gelatin, refluxing, solvent extracting, steam distilling, subliming, supercritical fluid extracting, membrane separating, micronizing, flocculation separating, semi-bionic extracting, ultrasonic extracting, cyclone extracting, pressure countercurrent extracting, enzyme extracting, macroporous resin adsorbing, ultrafiltering, and molecular distilling.
The invention also provides the application of the glycolipid-synergestic traditional Chinese medicine composition or traditional Chinese medicine extract in health products.
The invention also provides application of the glycolipid-synergestic traditional Chinese medicine composition or traditional Chinese medicine extract in preparing medicines for treating lipid-lowering and/or blood-lowering.
The invention also provides a preparation with the same glycolipid, which comprises the traditional Chinese medicine composition and/or the traditional Chinese medicine extract with the same glycolipid.
Preferably, the formulation includes, but is not limited to, granules, pills, tablets, powders, pastes or capsules.
The invention has the beneficial effects that:
(1) Under the guidance of the theory of the liver-regulating pivot-promoting turbid-removing method, fingered citron, chinese yam, hawthorn, momordica grosvenori, polygonatum and noni are selected as main raw materials, and the synergistic effect of the fingered citron, the momordica grosvenori and the noni is utilized to exert better effects of regulating blood sugar and blood fat and realize regulation of glycolipid from 'different' to 'and'.
(2) Meanwhile, in the technical scheme protected by the invention, when the weight ratio of the fingered citron to the momordica grosvenori to the noni fruit in the composition is 5:5:4, the regulation of glycolipids is optimal (better regulation of blood glucose and blood lipids).
(3) In addition, the raw materials of the invention are all taken from food raw materials, the safety is high, no damage is caused to other organs, the glycolipid is homologated, and the normal sugar and lipid levels are not influenced, so the invention can be used for a long time.
Detailed Description
The following embodiments of the present invention are provided by way of specific examples, and other advantages and effects of the present invention will be readily apparent to those skilled in the art from the disclosure herein. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Before the present embodiments are further described, it is to be understood that the scope of the invention is not to be limited to the specific embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The source of the raw materials adopted by the invention is not limited, and if no special description is provided, the raw materials adopted by the invention are all products which are sold on the market in the technical field, wherein the noni fruit is noni pulp, and the soluble solid content is 7.0-9.0%.
Basic embodiment
A Chinese medicinal composition with sugar and lipid concocting effects comprises fructus Citri Sarcodactylis, rhizoma Dioscoreae, fructus crataegi, fructus Siraitiae Grosvenorii and rhizoma Polygonati.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 8-15 parts of fingered citron, 15-32 parts of Chinese yam, 9-12 parts of hawthorn, 9-15 parts of momordica grosvenori and 16-25 parts of rhizoma polygonati.
Preferably, the traditional Chinese medicine composition also comprises 6-12 parts by weight of noni fruits.
The invention also provides a preparation method of the glycolipid-synergestic traditional Chinese medicine composition, which comprises the following steps:
s1, drying and crushing fingered citron, chinese yam, hawthorn, momordica grosvenori and sealwort according to the formula ratio to obtain fine powder with the particle size of 350-400 mu m;
and S2, mixing the fine powder obtained in the step S1 with noni fruit in a formula amount to obtain the traditional Chinese medicine composition.
The invention also provides a traditional Chinese medicine extract with the same glycolipid, which is extracted from the traditional Chinese medicine composition.
Specifically, the extraction includes, but is not limited to: water decoction, impregnation, percolation, modified gelatin, reflux, solvent extraction, steam distillation, sublimation, supercritical fluid extraction, membrane separation, micronization, flocculation separation of Chinese medicinal materials, semi-bionic extraction, ultrasonic extraction, cyclone extraction, pressure countercurrent extraction, enzyme method, macroporous resin adsorption, ultrafiltration, and molecular distillation.
The invention also provides application of the glycolipid-synergestic traditional Chinese medicine composition or traditional Chinese medicine extract in health products.
The invention also provides application of the traditional Chinese medicine composition or the traditional Chinese medicine extract with the same glycolipid in preparing medicines for reducing blood fat and/or blood sugar.
The invention also provides a preparation with the same glycolipid, which comprises the traditional Chinese medicine composition or the traditional Chinese medicine extract with the same glycolipid.
EXAMPLES 1-9A glycolipid-synergestic Chinese medicinal composition and process for preparing the same
The raw materials and the amounts (parts by weight) of the glycolipid-synergestic Chinese medicinal compositions described in examples 1-9 are shown in Table 1, wherein "-" means no additive.
TABLE 1
Raw materials Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Example 7 Example 8 Example 9
Fingered citron/portion 8 15 12 14 8 14 13 12 10
Chinese yam/portion 15 32 24 22 16 30 25 18 20
Hawthorn fruit/portion 9 12 10.5 11 9 12 10 11 10
Siraitia grosvenorii/portion 15 9 12 14 14 9 13 12 10
Polygonatum sibiricum 16 25 23 21 17 25 19 24 20
Noni fruit - - - - 6 12 9 10 8
The preparation method comprises the following steps:
s1, drying and crushing fingered citron, chinese yam, hawthorn, momordica grosvenori and sealwort according to the formula amount to obtain fine powder with the particle size of 400 mu m;
and S2, mixing the fine powder obtained in the step S1 with noni fruit in a formula amount to obtain the traditional Chinese medicine composition.
Comparative example 1
This comparative example differs from example 3 in that: the traditional Chinese medicine composition comprises 20 parts by weight of fingered citron, 22 parts by weight of Chinese yam, 11 parts by weight of hawthorn, 20 parts by weight of momordica grosvenori and 10 parts by weight of rhizoma polygonati.
Comparative example 2
This comparative example differs from example 9 in that: the traditional Chinese medicine composition is prepared by replacing noni with cinnamon powder with the particle size of 350 mu m.
Experimental example 1 evaluation of hypoglycemic and hypolipidemic effects
(1) Experimental animals: male SD rats, 160-200g in body weight.
(2) The molding method comprises the following steps: after 2 weeks of adaptive feeding, SD rats were randomly divided into a model group and a normal control group (8 rats) by body weight. The model group was fed with high-sugar and high-fat diet (lard 10%, egg yolk powder 5%, sucrose 20%, cholesterol 2.0%, cholate 1% and regular diet 62%), and the normal control group was fed with normal rat diet. After 6 weeks of feeding, the model group rats were intraperitoneally injected with a small dose of Streptozotocin (STZ) 40mg/kg for 12 hours on an empty stomach, dissolved with a citric acid buffer solution (pH 4.2) having a concentration of 0.1mmol/L, and a normal control group was injected with only the same dose of citric acid as a control. After 2 weeks, after the rats are fasted for 12 hours, blood is taken for measuring blood sugar, and the model building success is judged according to the condition that the fasting blood sugar is more than 11.1 mmol/L.
(3) Grouping and administration: 88 rats which are successfully modeled are selected and randomly divided into an experimental group 1-11 and a model control group according to the weight, wherein each group comprises 8 rats, the experimental group 1-11 is respectively administered with the traditional Chinese medicine composition prepared in the embodiments 1-9 and the comparative examples 1-2 by intragastric administration, the administration amounts of the experimental group 1-4 and the experimental group 10-11 are 8mg/kg, the administration amounts of the experimental group 5-9 are 6mg/kg, the intragastric administration is carried out for 1 time every day for 12 weeks, and the model control group and the normal control group are administered with physiological saline with the same volume.
After the administration, the rats are anesthetized and blood is taken out, and the rats are killed after the blood sugar and the blood fat are measured, wherein,
and (3) blood sugar detection: the tail tip is disinfected by 75% medicinal alcohol, then the tail is cut to take blood, and the blood sugar is detected by a surpassing JPS-5 type glucometer.
And (3) blood fat detection: blood was collected from the heart of each group of rats, which were placed in a 37% constant temperature water bath for 5 minutes, centrifuged at 3000 rpm (desk centrifuge) for 3 minutes, and the supernatant was collected and tested for TC and TG by a full-automatic biochemical analyzer, with the results shown in tables 2 and 3.
TABLE 2 fasting plasma glucose in rats
Figure BDA0003789661010000071
Group of Fasting blood glucose (mmol/L)
Normal control group 5.31±0.92
Model control group 19.36±3.42
Experimental group 1 13.97±2.54
Experimental group 2 13.88±2.48
Experimental group 3 13.17±2.15
Experimental group 4 13.60±2.35
Experimental group 5 13.35±1.87
Experimental group 6 13.13±1.75
Experimental group 7 12.95±1.54
Experimental group 8 12.53±1.15
Experimental group 9 11.09±1.01
Experimental group 10 18.54±2.67
Experimental group 11 15.02±2.11
As can be seen from the above table, compared with the model control group, the traditional Chinese medicine composition of the present invention can reduce fasting plasma glucose of rats, and meanwhile, as can be seen from examples 5 to 9, after morinda citrifolia is added, the blood glucose reducing effect of the traditional Chinese medicine composition of the present invention is further improved, and it is found that, when the weight ratio of fingered citron, momordica grosvenori and morinda citrifolia in the composition is 5:5:4, the effect of regulating blood sugar is better.
TABLE 3 Total serum Cholesterol and Triglycerides in rats
Figure BDA0003789661010000081
Group of Total cholesterol (mmol/L) Triglyceride (mmol/L)
Normal control group 1.62±0.20 0.84±0.16
Model control group 4.78±0.37 1.66±0.25
Experimental group 1 3.36±0.34 1.49±0.21
Experimental group 2 3.34±0.36 1.47±0.23
Experimental group 3 3.25±0.31 1.39±0.17
Experimental group 4 3.31±0.33 1.44±0.20
Experimental group 5 3.22±0.27 1.41±0.19
Experimental group 6 3.19±0.26 1.37±0.22
Experimental group 7 3.17±0.24 1.35±0.24
Experimental group 8 3.14±0.21 1.33±0.18
Experimental group 9 2.90±0.18 1.30±0.17
Experimental group 10 4.59±0.36 1.58±0.31
Experimental group 11 3.35±0.27 1.45±0.27
As can be seen from the above table, the traditional Chinese medicine composition of the present invention can reduce the total cholesterol and triglyceride contents compared with the model control group; after the morinda citrifolia is added, the lipid-lowering effect of the traditional Chinese medicine composition is further improved, and meanwhile, the weight ratio of the fingered citron to the momordica grosvenori to the morinda citrifolia in the composition is 5:5:4, the effect of regulating blood fat is better.
In conclusion, under the guidance of the theory of the method of regulating liver, promoting pivot and eliminating turbidity, fingered citron, chinese yam, hawthorn, momordica grosvenori, polygonatum and noni are selected as main raw materials, and the synergistic effect of the fingered citron, the momordica grosvenori and the noni is utilized to exert better blood sugar and blood fat regulating effect and realize the regulation of glycolipid from 'different' to 'different' and 'different'.
Meanwhile, in the technical scheme protected by the invention, when the weight ratio of the fingered citron to the momordica grosvenori to the morinda citrifolia in the composition is 5:5:4, the regulation of glycolipids is optimal (better regulation of blood glucose and blood lipids).
In addition, the raw materials of the invention are all taken from food raw materials, the safety is high, no damage effect is caused to other organs, and the glycolipid is homodyned, and the normal glycolipid level is not influenced, so the invention can be used for a long time.
The present invention has been further described with reference to specific embodiments, which are only exemplary and do not limit the scope of the present invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.

Claims (10)

1. A glycolipid-synergestic traditional Chinese medicine composition is characterized by comprising the following raw materials: fingered citron, chinese yam, hawthorn, momordica grosvenori and sealwort.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 8-15 parts of fingered citron, 15-32 parts of Chinese yam, 9-12 parts of hawthorn, 9-15 parts of momordica grosvenori and 16-25 parts of rhizoma polygonati.
3. The Chinese medicinal composition according to claim 1, wherein the Chinese medicinal composition further comprises 6-12 parts by weight of noni fruit.
4. The Chinese medicinal composition according to claim 3, wherein the noni fruit is noni pulp, and the soluble solid content is 7.0-9.0%.
5. The traditional Chinese medicine composition according to claim 3, wherein the weight ratio of the fingered citron, the momordica grosvenori and the noni is 5:5:4.
6. a method for preparing the Chinese medicinal composition of any one of claims 1 to 5, comprising the steps of:
s1, drying and crushing fingered citron, chinese yam, hawthorn, momordica grosvenori and sealwort according to the formula ratio to obtain fine powder;
and S2, mixing the fine powder obtained in the step S1 with noni fruit in a formula amount to obtain the traditional Chinese medicine composition.
7. A glycolipid-syngulated Chinese medicinal extract characterized by being extracted from the Chinese medicinal composition of any one of claims 1-6.
8. The extract of claim 7, wherein the extraction is at least one of water decoction, maceration, percolation, modified gelatin, reflux, solvent extraction, steam distillation, sublimation, supercritical fluid extraction, membrane separation, micronization, flocculation, semi-bionic extraction, ultrasonic extraction, cyclone extraction, pressure countercurrent extraction, enzymatic extraction, macroporous resin adsorption, ultrafiltration, and molecular distillation.
9. Use of the Chinese medicinal composition of any one of claims 1 to 5 or the Chinese medicinal extract of any one of claims 7 to 8 in the preparation of a medicament and/or health product for reducing blood lipid and/or blood sugar.
10. A preparation of glycolipids which is synergestic, comprising the traditional Chinese medicine composition of any one of claims 1-5 and/or the traditional Chinese medicine extract of any one of claims 7-8.
CN202210952235.5A 2022-08-09 2022-08-09 Glycolipid-coordinated traditional Chinese medicine composition, extract, preparation method, application and preparation Active CN115400189B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210952235.5A CN115400189B (en) 2022-08-09 2022-08-09 Glycolipid-coordinated traditional Chinese medicine composition, extract, preparation method, application and preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210952235.5A CN115400189B (en) 2022-08-09 2022-08-09 Glycolipid-coordinated traditional Chinese medicine composition, extract, preparation method, application and preparation

Publications (2)

Publication Number Publication Date
CN115400189A true CN115400189A (en) 2022-11-29
CN115400189B CN115400189B (en) 2023-12-29

Family

ID=84158680

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210952235.5A Active CN115400189B (en) 2022-08-09 2022-08-09 Glycolipid-coordinated traditional Chinese medicine composition, extract, preparation method, application and preparation

Country Status (1)

Country Link
CN (1) CN115400189B (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101120999A (en) * 2006-08-08 2008-02-13 芮育健 New use of traditional Chinese medicines rhizome polygonatum, cistanche, and multiflower knotweed root for blood-circulation-promoting vein-relaxing and treating diabetes
KR100831621B1 (en) * 2007-07-26 2008-05-27 (주)리드팜 The plant extracts composition for the blood glucose reducing action
US20090291154A1 (en) * 2004-12-10 2009-11-26 Tianjin Tasly Pharmaceutical Co., Ltd. pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof
US20110165273A1 (en) * 2008-09-05 2011-07-07 Jiao Guo A composition of extracts from plants and the use thereof in prophylaxis or treatment of metabolism disorder of blood lipid
CN109221551A (en) * 2018-11-20 2019-01-18 广西中医药大学 A kind of reducing blood lipid antioxidant health-care tea and preparation method thereof
CN109567175A (en) * 2019-01-18 2019-04-05 青岛科技大学 A kind of auxiliary hyperglycemic, compound Siraitia grosvenorii functional food of reducing blood lipid and preparation method thereof
CN111166820A (en) * 2020-01-20 2020-05-19 广东药科大学 Traditional Chinese medicine composition containing fingered citron, preparation and application

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090291154A1 (en) * 2004-12-10 2009-11-26 Tianjin Tasly Pharmaceutical Co., Ltd. pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof
CN101120999A (en) * 2006-08-08 2008-02-13 芮育健 New use of traditional Chinese medicines rhizome polygonatum, cistanche, and multiflower knotweed root for blood-circulation-promoting vein-relaxing and treating diabetes
KR100831621B1 (en) * 2007-07-26 2008-05-27 (주)리드팜 The plant extracts composition for the blood glucose reducing action
US20110165273A1 (en) * 2008-09-05 2011-07-07 Jiao Guo A composition of extracts from plants and the use thereof in prophylaxis or treatment of metabolism disorder of blood lipid
CN109221551A (en) * 2018-11-20 2019-01-18 广西中医药大学 A kind of reducing blood lipid antioxidant health-care tea and preparation method thereof
CN109567175A (en) * 2019-01-18 2019-04-05 青岛科技大学 A kind of auxiliary hyperglycemic, compound Siraitia grosvenorii functional food of reducing blood lipid and preparation method thereof
CN111166820A (en) * 2020-01-20 2020-05-19 广东药科大学 Traditional Chinese medicine composition containing fingered citron, preparation and application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
唐春萍,郭姣等: "调脂灵对高脂血症大鼠降脂作用的实验研究", 《中国实验方剂学杂志》, pages 188 - 27 *

Also Published As

Publication number Publication date
CN115400189B (en) 2023-12-29

Similar Documents

Publication Publication Date Title
KR100645385B1 (en) Composition for anti-obesity
Friday et al. Investigations on the nutritional and medicinal potentials of Ceiba pentandra leaf: A common vegetable in Nigeria
CN106942731A (en) A kind of nutrient powder eaten suitable for the three high patients and preparation method thereof
CN107951935A (en) A kind of pueraria lobata hoveniae semoveniae semen broken wall composition and its preparation method and application
KR20100013040A (en) Composition for prevention or treatment of diabete or obesity comprising punica granatum extract and red ginseng extract
CN110897147A (en) Dendrobium officinale alcohol-dispelling and liver-protecting composition and preparation method thereof
KR20080030844A (en) Composition for prevention of obesity containing a hot pepper extract and health supporting foods containing the same
JP6999175B2 (en) Oral composition
JP2018070570A (en) Lindera plant extract
CN107613998A (en) Contain the prevention and treatment pharmaceutical composition or healthy food of the metabolic disease of Pleurotus ferulae water extract as active ingredient
CN115400189B (en) Glycolipid-coordinated traditional Chinese medicine composition, extract, preparation method, application and preparation
KR101402852B1 (en) Fermented bellflower pills and Preparation thereof
JP2004352626A (en) Anticholesterol agent containing plant-derived component
CN109452417A (en) A kind of pure natural fat eliminating Weight reducing tea drink and preparation method thereof
CN104622993B (en) Chewable tablet with protective effect on alcoholic liver injuries and preparation method of chewable tablet
CN109316565B (en) Blood fat reducing composition and preparation method and application thereof
KR100496622B1 (en) Alcohol fermented food or pharmaceutical composition for prevention of obesity and process for preparation thereof
JP7409798B2 (en) Intestinal flora regulator
CN109805235B (en) Wheat-flavor composite polypeptide solid beverage for assisting in reducing hypertension, hyperglycemia and hyperlipidemia, and preparation method and application thereof
KR20050037444A (en) Composition of herb tea powder for anti-obeseness and liquid thereof
CN107441429A (en) A kind of sobering-up composition and preparation method thereof
KR20050068289A (en) Manufacturing method of functional berverage and food by using wax gourd,flavonoid and honey
CN109432141A (en) A kind of preparation method of Phellinus composition and the application in terms of medical treatment
CN111357902A (en) Functional beverage capable of reducing blood fat and preparation method thereof
CN102960719A (en) Preparation method of functional health food

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230407

Address after: No. 43-9085 Guangrao Road, Shibei District, Qingdao City, Shandong Province, 266023

Applicant after: Qingdao Lianhuasheng Medical Technology Co.,Ltd.

Address before: 510006 Panyu District, Guangzhou, Guangdong, 280 Panyu District road outside the city.

Applicant before: GUANGDONG PHARMACEUTICAL University

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231205

Address after: 910-A49, Building 5, Xiangtai Square, No. 129 Yingxiong Mountain Road, Liulishan Street, Shizhong District, Jinan City, Shandong Province, 250001

Applicant after: Jinan Changgeng Pharmaceutical Technology Co.,Ltd.

Address before: No. 43-9085 Guangrao Road, Shibei District, Qingdao City, Shandong Province, 266023

Applicant before: Qingdao Lianhuasheng Medical Technology Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant